X0306 four 2021-08-04 zero 0001652130 Intellia Therapeutics, Inc. NTLA 0001777421 Sepp-Lorenzino Laura C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 zero one zero zero EVP, Chief Scientific Officer Common Stock 2021-08-04 four M zero twenty-six thousand thirteen point four zero A twenty-eight thousand three hundred and ninety-one D Common Stock 2021-08-04 four S zero one thousand four hundred and seventy-one one hundred and thirty-five point four seven D twenty-six thousand nine hundred and twenty D Common Stock 2021-08-04 four S zero six thousand eight hundred and fourteen one hundred and thirty-six point seven nine D twenty thousand one hundred and six D Common Stock 2021-08-04 four S zero six thousand three hundred and forty-four one hundred and thirty-seven point seven two D thirteen thousand seven hundred and sixty-two D Common Stock 2021-08-04 four S zero four thousand four hundred and nineteen one hundred and thirty-eight point seven eight D nine thousand three hundred and forty-three D Common Stock 2021-08-04 four S zero two thousand seven hundred and seventy-two one hundred and thirty-nine point eight five D six thousand five hundred and seventy-one D Common Stock 2021-08-04 four S zero four thousand and fifty-four one hundred and forty point seven three D two thousand five hundred and seventeen D Common Stock 2021-08-04 four S zero one hundred and twenty-six one hundred and forty-one point six three D two thousand three hundred and ninety-one D Stock Option (right to buy) thirteen point four zero 2021-08-04 four M zero twenty-six thousand zero D 2030-03-01 Common Stock twenty-six thousand one hundred and nine thousand D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021. /s/ Glenn Goddard 2021-08-06